3-<3,5-dimethyl-4-<<3-<3-(trifluoromethyl)-5-isoxazolyl>propyl>oxy>phenyl>-5-methyl-1,2,4-oxadiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-<3,5-dimethyl-4-<<3-<3-(trifluoromethyl)-5-isoxazolyl>propyl>oxy>phenyl>-5-methyl-1,2,4-oxadiazole
• 英文别名: 5-{3-[2,6-Dimethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenoxy]propyl}-3-trifluoromethylisoxazole；3-[3,5-dimethyl-4-[3-[3-(trifluoromethyl)-1,2-oxazol-5-yl]propoxy]phenyl]-5-methyl-1,2,4-oxadiazole
• 化学式: C₁₈H₁₈F₃N₃O₃
• 分子量: 381.354
• InChiKey: ZBKSFPHDEQYTBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  74.2
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  7-[2,6-Dimethyl-4-(5-methyl-[1,2,4]oxadiazol-3-yl)-phenoxy]-1,1,1-trifluoro-hept-3-yn-2-one oxime 以 苯 为溶剂， 反应 18.0h， 生成 3-<3,5-dimethyl-4-<<3-<3-(trifluoromethyl)-5-isoxazolyl>propyl>oxy>phenyl>-5-methyl-1,2,4-oxadiazole
  参考文献：
  名称：

  Picornavirus Inhibitors: Trifluoromethyl Substitution Provides a Global Protective Effect against Hepatic Metabolism

  摘要：

  Several modifications of the oxazoline ring of WIN 54954, a broad spectrum antipicornavirus compound, have been prepared in order to address the acid lability and metabolic instability of this compound. We have previously shown that the oxadiazole analogue 3 displayed comparable activity against a variety of rhinoviruses and appeared to be stable to acid. A monkey liver microsomal assay was developed to examine the metabolic stability in vitro of both compounds, and it was determined that WIN 54954 displayed 18 metabolic products while 3 was converted to 8 products. Two major products of 3 were determined by LC-MS/MS to be monohydroxylated at each of the terminal methyl groups. Replacement of the methyl on the isoxazole ring with a trifluoromethyl group, while preventing hydroxylation at this position, did not reduce the sensitivity of the molecule to microsomal metabolism at other sites. However, the (trifluoromethyl)oxadiazole 9 not only prevented hydroxylation at this position but also provided protection at the isoxazole end of the molecule, resulting in only two minor products to the extent of 4%. The major product was identified as the monohydroxylated compound 23. The global metabolic protective effect of trifluoromethyl group on the oxadiazole ring was further demonstrated by examining a variety of analogues including heterocyclic replacements of the isoxazole ring. In each case, the trifluoromethyl analogue displayed a protective effect when compared to the corresponding methyl analogue.

  DOI：

  10.1021/jm00008a014

文献信息

• 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral
  申请人：Sterling Drug Inc.

  公开号：US05175177A1

  公开（公告）日：1992-12-29

  Compounds of the formula ##STR1## wherein: Y is alkylene of 3 to 9 carbon atoms; R.sub.1 is lower-alkyl, lower-alkoxy-(C.sub.1-3 -alkyl), lower-alkoxycarbonyl, cyclopropyl or trifluoromethyl; R.sub.2 and R.sub.3 independently are hydrogen, lower-alkyl, halogen, lower-alkoxy, nitro, trifluoromethyl or hydroxy; and R.sub.4 is hydrogen or lower-alkyl; where lower-alkyl and lower-alkoxy, each occurrence, have from 1-5 carbon atoms; with the proviso that when R.sub.1 is lower-alkyl, at least one of R.sub.2 and R.sub.3 is hydroxy; or pharmaceutically acceptable acid-addition salts thereof are useful as antiviral agents, particularly against picornaviruses, including numerous strains of rhinovirus.

  分子式为##STR1##的化合物，其中：Y为3到9个碳原子的烷基；R.sub.1为低烷基，低烷氧基-(C.sub.1-3-烷基)，低烷氧羰基，环丙基或三氟甲基；R.sub.2和R.sub.3独立地为氢，低烷基，卤素，低烷氧基，硝基，三氟甲基或羟基；R.sub.4为氢或低烷基；其中，每次出现的低烷基和低烷氧基均具有1-5个碳原子；但当R.sub.1为低烷基时，至少有R.sub.2和R.sub.3中的一个为羟基；或其药学上可接受的酸加成盐可用作抗病毒剂，特别是对抗多种鼻病毒菌株的畏克病毒。
• 1,2,4-Oxadiazolyl-phenoxy-alkylisoxazoles and their use as antiviral agents
  申请人：STERLING WINTHROP INC.

  公开号：EP0523803A1

  公开（公告）日：1993-01-20

  Compounds of the formula wherein:    Y is alkylene of 3 to 9 carbon atoms;    R₁ is lower-alkyl, lower-alkoxy-(C₁₋₃-alkyl), lower-alkoxycarbonyl, cyclopropyl or trifluoromethyl;    R₂ and R₃ independently are hydrogen, lower-alkyl, halogen, lower-alkoxy, nitro, trifluoromethyl or hydroxy; and    R₄ is hydrogen or lower-alkyl; where lower-alkyl and lower-alkoxy, each occurrence, have from 1-5 carbon atoms;    with the proviso that when R₁ is lower-alkyl, at least one of R₂ and R₃ is hydroxy; or pharmaceutically acceptable acid-addition salts thereof, are useful as antiviral agents, particularly against picornaviruses, including numerous strains of rhinovirus.

  式中的化合物 其中 Y 是 3 至 9 个碳原子的亚烷基； R₁ 是低级烷基、低级烷氧基（C₁₋₃-烷基）、低级烷氧基羰基、环丙基或三氟甲基； R₂ 和 R₃ 独立地为氢、低级烷基、卤素、低级烷氧基、硝基、三氟甲基或羟基；以及 R₄ 是氢或低级烷基；其中低级烷基和低级烷氧基各自具有 1-5 个碳原子； 但当 R₁ 是低级烷基时，R₂ 和 R₃ 中至少有一个是羟基；或其药学上可接受的酸加成盐、 可用作抗病毒剂，尤其是抗皮卡病毒，包括多种鼻病毒株。
• US5175177A
  申请人：——

  公开号：US5175177A

  公开（公告）日：1992-12-29
• Picornavirus Inhibitors: Trifluoromethyl Substitution Provides a Global Protective Effect against Hepatic Metabolism
  作者：Guy D. Diana、Patrick Rudewicz、Daniel C. Pevear、Theodore J. Nitz、Suzanne C. Aldous、David J. Aldous、David T. Robinson、Tandy Draper、Frank J. Dutko、Christopher Aldi、Guy Gendron、R. Christopher Oglesby、Deborah L. Volkots、Michael Reuman、Thomas R. Bailey、Richard Czerniak、Tracey Block、Robert Roland、James Oppermann

  DOI：10.1021/jm00008a014

  日期：1995.4.1

  Several modifications of the oxazoline ring of WIN 54954, a broad spectrum antipicornavirus compound, have been prepared in order to address the acid lability and metabolic instability of this compound. We have previously shown that the oxadiazole analogue 3 displayed comparable activity against a variety of rhinoviruses and appeared to be stable to acid. A monkey liver microsomal assay was developed to examine the metabolic stability in vitro of both compounds, and it was determined that WIN 54954 displayed 18 metabolic products while 3 was converted to 8 products. Two major products of 3 were determined by LC-MS/MS to be monohydroxylated at each of the terminal methyl groups. Replacement of the methyl on the isoxazole ring with a trifluoromethyl group, while preventing hydroxylation at this position, did not reduce the sensitivity of the molecule to microsomal metabolism at other sites. However, the (trifluoromethyl)oxadiazole 9 not only prevented hydroxylation at this position but also provided protection at the isoxazole end of the molecule, resulting in only two minor products to the extent of 4%. The major product was identified as the monohydroxylated compound 23. The global metabolic protective effect of trifluoromethyl group on the oxadiazole ring was further demonstrated by examining a variety of analogues including heterocyclic replacements of the isoxazole ring. In each case, the trifluoromethyl analogue displayed a protective effect when compared to the corresponding methyl analogue.